Fig. 2From: Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumabEfficacy endpoint assessment results (mITT population). *-Pearson's Chi-square test with Yates' correction. **-exact Fisher's testBack to article page